DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for polymyositis — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePolymyositis maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for polymyositis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 12B (IL12B) — IL12B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5MJ3 · 1.74 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
Two groups of patients with polymyositis were followed for roughly three years in a 1981 study. One group received prednisone alone, the other prednisone plus azathioprine. At three months no statistically significant difference was noted between the groups. Longer follow-up showed that the group given both drugs improved more with respect to functional disability and required less prednisone for disease control.
A 2012 review noted that there are few clinical trials in myositis, making clear treatment recommendations difficult. Current management begins with corticosteroids followed by second-line drugs such as methotrexate and azathioprine, which have not been tested in rigorous randomised controlled trials but are used by expert consensus. Intravenous immunoglobulin showed proven benefit in one controlled trial as a short-term treatment. Cyclosporine or tacrolimus showed efficacy in myositis including patients with interstitial lung disease, and mycophenolate mofetil was effective in both polymyositis and refractory dermatomyositis. Uncontrolled studies for rituximab were encouraging, but the largest randomised controlled trial in myositis failed to meet its primary endpoint. Anti-TNF agents showed mixed results: infliximab demonstrated no benefit, while etanercept produced encouraging results warranting further study. The review concluded that no major breakthroughs have been realised.
A 2021 overview described polymyositis as an autoimmune disorder developing over months. The 5-year survival rate for treated patients is about 95%. Up to one-third of patients may be left with some degree of residual muscle weakness. Many patients require treatment for several years.
What is still missing are large, rigorous randomised controlled trials that could provide clear evidence for the drugs currently used by consensus. The rarity of the disease makes trial design and patient stratification difficult, and funding for such trials remains limited. No drug has been shown to eliminate residual muscle weakness in the substantial minority of patients who experience it.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Arthritis & Rheumatism · 1981 · 263 citations
Prednisone and azathioprine for polymyositis. Long‐term followup
AbstractTwo groups of patients with polymyositis have been followed for approximately 3 years. One group was treated with prednisone alone and the other with prednisone plus azathioprine. Although the polymyositis of both groups has improved, no statistically significant difference was noted at the end of 3 months, as previously reported. Longer followup, however, has shown that the group given prednisone plus azathioprine has improved more with respect to functional disability; this group also requires less prednisone for disease control.
Current Opinion in Rheumatology · 2012 · 61 citations
Therapeutic advances in myositis
AbstractPURPOSE OF REVIEW: To review the treatment advances of the inflammatory myopathies, a heterogeneous group of diseases that includes polymyositis, dermatomyositis, and inclusion body myositis. RECENT FINDINGS: There are few clinical trials in myositis, making it difficult to provide clear recommendations on the treatment of these rare disorders. The current management for IIM includes the initial use of corticosteroids followed by various conventional second-line treatments such as methotrexate and azathioprine. Although these drugs have not been tested in rigorous randomized controlled trials, general expert consensus confirms their use. Intravenous immunoglobulin is a reasonable short-term treatment with proven benefit in one controlled trial, although the evidence for other immunosuppressive therapies has been derived mainly from uncontrolled studies. Cyclosporine or tacrolimus have shown efficacy in myositis including those patients with interstitial lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis and refractory dermatomyosits (including recalcitrant rash) and ILD. Uncontrolled studies for rituximab are encouraging but results from the largest randomized controlled trial in myositis failed to meet the primary endpoint. Anti-tumor necrosis factor (TNF) agents have shown mixed results in small, randomized clinical trials with infliximab demonstrating no benefit and etanercept leading to encouraging results warranting further study. Some newer novel therapies such as ACTH analogues and tocilizumab require additional investigation. SUMMARY: The balance of evidence suggests that traditional immunosuppressive and immunomodulatory drugs are certainly effective in polymyositis and dermatomyositis despite the lack of randomized controlled trials. Newer therapies are being studied but no major breakthroughs have been realized.
Journal of Pharmaceutical Research International · 2021 · 1 citations · open access
Overview on Diagnosis and Management of Polymyositis
AbstractPolymyositis (PM) is an autoimmune disorder; result from abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex class 1 causing damage to the endomysium of the skeletal muscles. Polymyositis develops over the months as compared to inclusion body myositis (IBM), which is a slowly progressive chronic myopathy developing in older individuals over a period of months to years with more severe symptoms. Many patients require treatment for many years. Polymyositis affects the distal musculature of the esophagus in the late stage of disease in up to 70% of the patients leading to the inability to swallow, as well as regurgitation problems that can cause aspiration pneumonia. The principal goals of therapy are to improve strength and improve physical functioning. Many patients require treatment for several years. The 5-year survival rate for treated patients is in the order of 95%. Up to one-third of PM patients may be left with some degree of residual muscle weakness.
Journal of Rheumatic Diseases · 2009 · 0 citations · open access
A Case of Resistant Polymyositis That Was Successfully Treated with Tacrolimus
AbstractPolymyositis is one form of inflammatory myopathy. In some patients, this disease does not entirely respond to conventional initial therapy with glucocorticoid, methotrexate and azathioprine. Multiple options exist for treating these patients, but only intravenous immune globulin has been subjected to a randomized clinical trial. We report here on a case of polymyositis that did not respond to multiple drug therapy, but it did respond to tacrolimus. After treatment with tacrolimus, the patient's disease has been well controlled for many years.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
